文献速递前列腺增生与排尿功能障碍

影响膀胱过度活动症治疗药物选择的因素:来自AUA质量登记的趋势与洞察

Factors Influencing Medication Selection for Management of Overactive Bladder: Trends and Insights From AUA Quality Registry.
PubMed 文献 · Urology · 2023-12-09

基于AUA质量登记2014至2020年1453566例膀胱过度活动症(OAB)患者数据,其中641122例(44.1%)资料完整,112021例(17.5%)被处方药物。多因素分析显示,医疗补助、医疗保险及其他/自费保险患者较私人或军人保险者接受β-3受体激动剂而非抗胆碱能药物的可能性更低;亚裔、黑人及其他种族较白人更低,非大都市地区患者亦更低;年龄>50岁、2014年后处方及非学术机构与β-3受体激动剂处方几率增加相关;性别间无差异。

要点

  • 保险类型和种族等非临床因素可能影响OAB首选药物。
  • 医疗补助、医疗保险及其他/自费保险患者接受β-3受体激动剂几率低于私人或军人保险。
  • 亚裔、黑人及其他种族患者接受β-3受体激动剂几率低于白人患者。

核心结论

  • 许多非临床因素,包括保险类型和种族,可能影响OAB首次处方药物的选择。
  • 该结果对执业泌尿外科医生有用,并可能通过政策改变和倡导帮助降低β-3受体激动剂处方的障碍。

研究设计与样本

  • 查询AUA质量登记中2014年至2020年间诊断为OAB超过1年的成人患者,排除神经源性病因。
  • 共纳入1453566例OAB患者,其中641122例(44.1%)资料完整,112021例(17.5%)被处方药物。
  • 变量包括年龄、种族/民族、性别、保险类型、首次处方药物、处方年份、提供者大都市状态和提供者执业类型。
  • 主要结局是与β-3受体激动剂作为首次药物选择几率增加相关的因素。

主要发现

  • 多因素分析中,医疗补助、医疗保险及其他/自费保险患者较私人或军人保险者接受β-3受体激动剂而非抗胆碱能药物的可能性更低。
  • 与白人患者相比,亚裔、黑人及其他种族患者接受β-3受体激动剂的可能性更低,大都市地区以外的患者亦更低。
  • 年龄>50岁、2014年后处方及非学术机构与β-3受体激动剂处方几率增加相关。
  • 性别间无差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine how a patient's demographics, including insurance type, race/ethnicity, gender, and age, may impact the choice of medication prescribed for overactive bladder (OAB). METHODS: We queried the AUA Quality Registry for adults between 2014 and 2020 with a diagnosis of OAB for >1year, excluding neurogenic causes. Variables included age, race/ethnicity, gender, insurance type, medication first prescribed, year of prescription, provider metropolitan status, and provider practice type. Primary outcome was which factors were associated with increased odds of beta-3 prescription as first medication choice. RESULTS: We found 1,453,566 patients with OAB, 641,122 (44.1%) with complete data. Of these, 112,021 (17.5%) were prescribed medication. On multivariate analysis, patients with Medicaid, Medicare, and other/self-pay insurance were less likely to receive a beta-3 vs an anticholinergic compared to private or military insurance. Compared to white patients, Asian, Black, and other races were less likely to receive a beta-3, as were patients outside of metropolitan areas. Age >50, prescriptions after 2014, and nonacademic settings were associated with increased odds of beta-3 prescription. There was no difference between genders. CONCLUSION: Many nonclinical factors, including insurance type and race, may affect which medication is first prescribed for OAB. This is useful for practicing urologists and may help lower barriers to beta-3 prescription through policy change and advocacy.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Bowman M, Vélez CA, Jericevic D, et al. Factors Influencing Medication Selection for Management of Overactive Bladder: Trends and Insights From AUA Quality Registry. Urology. 2023. PMID: 38081481. doi:10.1016/j.urology.2023.11.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。